Identification of a non-competitive inhibitor of Plasmodium falciparum aspartate transcarbamoylase

Biochem Biophys Res Commun. 2018 Mar 11;497(3):835-842. doi: 10.1016/j.bbrc.2018.02.112. Epub 2018 Feb 21.

Abstract

Aspartate transcarbamoylase catalyzes the second step of de-novo pyrimidine biosynthesis. As malarial parasites lack pyrimidine salvage machinery and rely on de-novo production for growth and proliferation, this pathway is a target for drug discovery. Previously, an apo crystal structure of aspartate transcarbamoylase from Plasmodium falciparum (PfATC) in its T-state has been reported. Here we present crystal structures of PfATC in the liganded R-state as well as in complex with the novel inhibitor, 2,3-napthalenediol, identified by high-throughput screening. Our data shows that 2,3-napthalediol binds in close proximity to the active site, implying an allosteric mechanism of inhibition. Furthermore, we report biophysical characterization of 2,3-napthalenediol. These data provide a promising starting point for structure based drug design targeting PfATC and malarial de-novo pyrimidine biosynthesis.

Keywords: 2,3-napthalenediol; Aspartate transcarbamoylase; Inhibitor; Malaria; Pyrimidine biosynthesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiparasitic Agents / chemistry*
  • Antiparasitic Agents / pharmacology*
  • Aspartate Carbamoyltransferase / antagonists & inhibitors*
  • Aspartate Carbamoyltransferase / chemistry
  • Aspartate Carbamoyltransferase / metabolism
  • Catalytic Domain / drug effects
  • Crystallography, X-Ray
  • Drug Discovery
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Malaria, Falciparum / drug therapy
  • Malaria, Falciparum / parasitology
  • Molecular Docking Simulation
  • Plasmodium falciparum / chemistry
  • Plasmodium falciparum / drug effects
  • Plasmodium falciparum / enzymology*

Substances

  • Antiparasitic Agents
  • Enzyme Inhibitors
  • Aspartate Carbamoyltransferase